<DOC>
	<DOCNO>NCT00032747</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , parallel-group force up-titration study . Randomization stratify accord patient 's baseline serum sodium concentration ( 137-144 &lt; 137 mmol/L ) . The dose study drug increase next level Day 15 , total duration double-blind treatment period 120 day .</brief_summary>
	<brief_title>Safety Study Vasopressin V2 Receptor Antagonist Patients With Severe Chronic Heart Failure ( AQUAVIT ) .</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Vasopressins</mesh_term>
	<mesh_term>Arginine Vasopressin</mesh_term>
	<criteria>Men woman chronic heart failure ( NYHA Class IIIB IV ) . Women must postmenopausal surgically sterilize ; pregnant nursing . Age 21 80 year . Chronic heart failure least 3 month duration . For 2 month prior screen , patient must symptoms rest minimal exertion 50 % time . For 2 week prior screen , patient must symptoms rest minimal exertion 90 % time . Patients must receive diuretic ACE inhibitor ( angiotensin II receptor antagonist ) treatment heart failure . Patients may receive digoxin , betablocker spironolactone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Chronic Heart Failure</keyword>
	<keyword>Heart Disease</keyword>
</DOC>